ArticleClinical rheumatology2009
A score of risk factors associated with ischemic digital ulcers in patients affected by systemic sclerosis treated with iloprost.
Article in Clinical rheumatology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 52 citations in OpenAlex.
- The Impact of Tobacco Smoking on Systemic Sclerosis, Idiopathic Inflammatory Myositis, and Systemic Lupus Erythematosus.Clinical medicine insights. Arthritis and musculoskeletal disorders · 2024Review
- Real life use of prostacyclin analog (iloprost), a multi-centric survey data from the Scleroderma study group Emilia Romagna (Sclero-RER) and review of the literature.Acta bio-medica : Atenei Parmensis · 2023Review
- Iguratimod as an alternative therapy for systemic sclerosis and prevention of the occurrence of ischemic digital ulcer.Frontiers in medicine · 2023Article
- The Relationship between Smoking, Raynaud's Phenomenon, Digital Ulcers, and Skin Thickness in the Waikato Systemic Sclerosis Cohort.Rheumatology and immunology research · 2022Article
- Iloprost Duration for Digital Ulcers in Systemic Sclerosis: French Retrospective Study at Two Centers and Literature Review.Frontiers in medicine · 2022Article
- Higher body mass index is associated with a lower iloprost infusion rate tolerance and higher iloprost-related adverse events in patients with systemic sclerosis.Therapeutic advances in musculoskeletal disease · 2022Article
- Reduction of fat free mass index and phase angle is a risk factor for development digital ulcers in systemic sclerosis patients.Clinical rheumatology · 2020Article
- Older age onset of systemic sclerosis - accelerated disease progression in all disease subsets.Rheumatology (Oxford, England) · 2020Article
- The first composite score predicting Digital Ulcers in systemic sclerosis patients using Clinical data, Imaging and Patient history-CIP-DUS.Arthritis research & therapy · 2020Article
- Raynaud phenomenon and digital ulcers in systemic sclerosis.Nature reviews. Rheumatology · 2020Review
- Iloprost use and medical management of systemic sclerosis-related vasculopathy in Italian tertiary referral centers: results from the PROSIT study.Clinical and experimental medicine · 2019Observational
- The safety of iloprost in systemic sclerosis in a real-life experience.Clinical rheumatology · 2018Article
- Long-term clinical stabilization of scleroderma patients treated with a chronic and intensive IV iloprost regimen.Rheumatology international · 2017Article
- User preference for a portable syringe pump for iloprost infusion.Patient related outcome measures · 2015Article
- [Therapeutic management in early disease stages of systemic sclerosis : early diagnosis - early symptoms - early problems].Zeitschrift fur Rheumatologie · 2013Review
- Bosentan fosters microvascular de-remodelling in systemic sclerosis.Clinical rheumatology · 2012Article
- Severe vascular complications in patients affected by systemic sclerosis cyclically treated with iloprost.Rheumatology international · 2012Article
- [Critical limb ischemia in systemic sclerosis].Zeitschrift fur Rheumatologie · 2012Article
- Assessing microvascular changes in systemic sclerosis diagnosis and management.Nature reviews. Rheumatology · 2010Review
- Raynaud's phenomenon and digital ischemia: a practical approach to risk stratification, diagnosis and management.International journal of clinical rheumatologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A single series of patients affected by systemic sclerosis (SSc) and cyclically treated with iloprost was reviewed in order to evaluate the incidence of digital ulcers (DUs) and to compare the characteristics between the patients with and without this painful and disabling vascular complication. The record charts of 85 SSc patients were revised. Ischemic DUs and scleroderma contracture ulcers were separately considered. Twenty-nine subjects developed ischemic DUs during the course of the disease; whereas, scleroderma contracture ulcers occurred in six subjects. Ischemic DUs were associated with younger age at scleroderma onset, a longer disease duration, a longer time delay from scleroderma diagnosis to iloprost therapy, a bigger skin involvement, the presence of joint contractures, a videocapillaroscopic late pattern, a history of smoking, and of corticosteroids therapy. After the exclusion of four subjects with concomitant peripheral arterial disease, a forward-stepwise logistic regression analysis showed that only four variables, i.e., age at scleroderma onset, delay in beginning iloprost therapy, history of smoking, and presence of joint contractures remained significantly associated with ischemic DUs. In a score reflecting the sum of these four risk factors, the prevalence of ischemic DUs increased progressively from the lowest to the highest value of the score. The predictivity of this model was evaluated by the receiver-operating characteristics curve, with an estimated area under the curve of 0.836 with 95% confidence interval from 0.736 to 0.937. All the patients with scleroderma contracture ulcers were characterized by both diffuse pattern of disease and positivity for anti-Scl70 antibody. In this retrospective study, scleroderma patients with ischemic DUs are characterized by early disease onset, delay in beginning iloprost therapy, smoking habit, and presence of joint contraction. A score reflecting the sum of these factors may be useful to predict the risk of developing ischemic DUs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.